3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
21
Rectal Neoplasms
10
Colonic Neoplasms
6
Pancreatic Neoplasms
4
Stomach Neoplasms
3
Neoplasm Metastasis
3
Adenocarcinoma Of Esophagus
3
Peritoneal Neoplasms
2
Neoplasms
2
Liver Neoplasms
2
Esophageal Neoplasms
2
Pancreatic Adenocarcinoma
1
Ovarian Neoplasms
1
Neuropathy, Painful
1
Neuralgia
1
Neoplasm Recurrence, Local
1
Malignant Solid Tumour
1
Locally Advanced Pancreatic Carcinoma(LAPC)
1
Gallbladder Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Disease Progression
1
Cold Hypersensitivity
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Carcinoma, Basal Cell
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Advanced Rectal Cancer
1
Advanced Primary Liver Cancer
1
Adenocarcinoma of the Lower Rectum
1
Interventions
Lenalidomide
3
Bortezomib
3
Dexamethasone
2
vandetanib
1
umbralisib
1
ublituximab
1
marizomib
1
durvalumab
1
carotuximab
1
avelumab
1
Zoledronic Acid
1
Vitamin D
1
Transplantation, Autologous
1
Tamoxifen
1
Standard of Care
1
Practice Guidelines as Topic
1
Palliative Care
1
Oxaliplatin
1
Melphalan
1
Leucovorin
1
Irinotecan
1
Granulocyte Colony-Stimulating Factor
1
Gemcitabine
1
Folfox protocol
1
Fluorouracil
1
Filgrastim
1
Cyclophosphamide
1
Cisplatin
1
Carboplatin
1
Calcium Dobesilate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Disease Progression
×
Folfox protocol
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts